In turn, assessing the prevalence of bortezomib-resistant constitutive NF-κB activity in MCL patient samples illuminates whether proteasome inhibition can efficiently abrogate constitutive NF-κB activity MCL patients. This evidence concerns the gene NFKB1 and mantle cell lymphoma.